Drugs / DEKAS plus
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT01773278 | Dec 2008 → Dec 2025 | Smith-Lemli-Opitz syndrome, cone-rod dystrophy, hearing loss disorder | University of Colorado, Denver | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DEKAS plus | “Patients will be prescribed the drug DEKAS plus at a dose based on age and weight.” NCT01773278 ↗ |
| Modality | Other / unclassified | “a mixture of vitamins and other compounds with antioxidant properties” NCT01773278 ↗ |